News and Publications

Latest News

The Emory Children’s Center-Vaccine Research Clinic team was recognized by Emory School of Medicine at the 2025 Staff Awards. Our team received the Team Excellence Award: Research/Science.

Link to 2025 SOM Staff Awards

In the CCIV 2023 Year in Review Newsletter, Dr. Satoshi Kamidani is featured on page 6 for leading the newly awarded CDC contract for the CISA Project.

Link to CCIV 2023 Year in Review

Emory Children's Center- Vaccine Research Clinic is featured on page 33 for participation in the clinical trial leading to U.S. FDA approval of an immunization for respiratory syncytial virus (RSV) infections.

Link to CHOA and Emory 2023 Research Report

The Emory Children's Center - Vaccine Research Clinic was a site for the Mix-and-Match study for COVID-19 vaccines, which was featured in the Emory University News in early 2022.

Link to Emory News Center article

Emory Children's Center - Vaccine Research Clinic was featured in the Spring 2022 issue of Emory Medicine Magazine highlighting our young volunteers participating in children's COVID-19 vaccine research studies.

Link to Emory Medicine Magazine article

Publications

Below are publications that we want to highlight.

News and Publications

Latest News

Publications

Clinical Progression Scale-Pediatrics: A Potential Metric of Respiratory Syncytial Virus Severity and Progression in Children

A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults

A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18–45 years of age

All-Cause and Pneumococcal Community-Acquired Pneumonia Hospitalizations Among Adults in Tennessee and Georgia

Differential severity of SARS-CoV-2 variant infections in children and adults with COVID-19

Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial

Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials

Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age

Evaluation of Immunoglobulin A Enzyme Immunoassays to Detect Primary Respiratory Syncytial Virus Infection in Infants and Young Children

Fc-effector functional antibody assays for SARS-CoV-2 variants of concern

Future Goals and Long-term Vision of the Infectious Diseases Clinical Research Consortium/Vaccine and Treatment Evaluation Unit Network

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost

Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants— 24 States, December 2024–April 2025

Serologic Responses to COVID-19 Vaccination in Pediatric Kidney Transplant Recipients

The XBB.1.5 COVID- 19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS- CoV- 2 spike proteins

Viral Etiologies of Acute Respiratory Illness in Older Adults and of Congestive Heart Failure and Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization During 2 Prepandemic Respiratory Seasons